McKesson Boosts FY21 Adj. EPS Outlook; Authorizes $2 Bln Share Buyback - Quick Facts

While reporting financial results for the third quarter on Tuesday, McKesson Corp. (MCK) raised its adjusted earnings guidance for the full-year 2021 to reflect improved growth in the business and the contribution from its successful distribution of COVID-19 vaccines and ancillary supplies.

For fiscal 2021, the company now projects adjusted earnings in a range of $ $16.95 to $17.25 per share, up from the previous guidance range of $16.00 to $16.50 per share.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $16.42 per share for the year. Analysts' estimates typically exclude special items.

Additionally, McKesson's Board of Directors authorized an additional $2.0 billion share repurchase program, demonstrating confidence in McKesson's diversified capital allocation strategy.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Activity in the U.S. manufacturing sector slowed by more than expected in the month of September but still saw continued growth, according to a report released by the Institute for Supply Management on Monday. Stocks have moved sharply higher in morning trading on Monday, regaining ground following a dismal September. The major averages have all shown substantial moves to the upside. Swedish geneticist Svante Paabo has won this year's Nobel Prize in Physiology/Medicine for his discoveries concerning the genomes of extinct hominins and human evolution. Through his pioneering research, Svante Pääbo accomplished something seemingly impossible: sequencing the genome of the Neanderthal, an extinct relative of present-day humans. He also made the sensational discovery of a previous
Follow RTT